赛立奇单抗第16周ASAS20达标率略优于竞品-行业数据

赛立奇单抗第16周ASAS20达标率略优于竞品

赛立奇单抗在治疗强直性脊柱炎 ASAS20达标率上略优于竞品。针对强直性脊柱炎适应症，II期临床数据结果表明，赛立奇单抗在 0-16周的 ASAS20达标率均明显优于安慰剂组。同时，IL-17A、JAK、TNF-α等不同靶点药物疗效横向比较，第 16周各组 ASAS20达标率整体相近，赛立奇单抗略优于竞品。

其它

下载图片

原图定位

同报告图片

/ 4

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